An investigation on behalf of investors in Eyenovia, Inc. (NASDAQ: EYEN) shares over potential wrongdoing at Eyenovia, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 09/20/2018 -- An investigation on behalf of investors in shares of Eyenovia, Inc. (NASDAQ: EYEN) was announced concerning possible breaches of fiduciary duties by certain officers and directors at Eyenovia, Inc. .
Investors who purchased shares of Eyenovia, Inc. (NASDAQ: EYEN) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Eyenovia directors breached their fiduciary duties and caused damage to the company and its shareholders.
New York based Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. Eyenovia, Inc. went public in January 2018. Since then shares of Eyenovia, Inc. (NASDAQ: EYEN) declined from $10.74 per share on January 25, 2018 to as low as $7.63 per share on May 25, 2018.
Those who purchased shares of Eyenovia, Inc. (NASDAQ: EYEN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels